Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Variant-Adapted BNT162b2 Vaccine in Healthy Adults 50-64 Years of Age
NCT07300839Phase 3Completed
- Sponsor
- BioNTech SE
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BNT162b2 Vaccine with Placebo (2 arms). Primary endpoints: Percentage of participants reporting local reactions or systemic events at 7 days, Percentage of participants reporting adverse events at 4 weeks and 2 more. Started Dec 2025; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07300839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300839.